Longevity's Safety Seal: Avaí Bio De-Risks Future of Anti-Aging Therapy

LAS VEGAS, NV – September 15, 2026 – In the burgeoning and fiercely competitive field of longevity science, where promises often outpace progress, a critical, tangible step forward has been achieved. Avaí Bio, Inc. (OTCQB: AVAI), an emerging biotechnology firm, and its global partner Austrianova today announced a milestone that, while not a clinical cure, represents a vital de-risking of their ambitious anti-aging therapy. The joint venture has successfully completed comprehensive safety testing of its GMP Master Cell Bank (MCB), the foundational source for its therapy designed to produce α-Klotho, the so-called “longevity protein.”

This achievement, which includes the subsequent establishment of a Working Cell Bank (WCB), serves as a regulatory and scientific seal of approval on the very building blocks of the potential treatment. It confirms the cells are free from a vast array of viruses and contaminants, a non-negotiable prerequisite for any therapy intended for human use. For investors and industry observers navigating the hype-filled longevity market, this kind of foundational progress is a powerful signal of a program built on scientific rigor rather than just speculative promise.

“We are pleased to announce the successful completion of this important testing milestone,” said Chris Winter, Chief Executive Officer of Avaí Bio. “The results provide additional confirmation of the safety and quality of our Master and Working Cell Banks and allow us, together with our partner, to advance the next stages of development.”

The Foundation of Trust: De-risking a Novel Therapy

Before a single patient can be enrolled in a trial, companies developing cell-based therapies must prove their manufacturing process is safe, consistent, and controllable. The creation of a Master Cell Bank under Good Manufacturing Practices (GMP) is the cornerstone of this process. It is a single, pristine batch of cells, cryopreserved and stored, from which all future production runs will originate. This ensures that the therapy administered in year five of a clinical program is identical to the one used in year one.

The testing announced by the partners was exhaustive. Conducted by an accredited third-party lab following U.S. Food and Drug Administration (FDA) guidelines, the cell bank was screened for over 30 viruses, including significant human pathogens like HIV, hepatitis B and C, and human cytomegalovirus. The analysis also confirmed the absence of other potential contaminants such as bacteria, mycoplasma, and fungi. Passing this gauntlet is a critical gate-keeping step in the long journey of drug development.

“Comprehensive testing of cell banks for viruses and other adventitious agents is an essential component of biomanufacturing and an important prerequisite for advancing cell-based products toward clinical development,” noted Dr. Brian Salmons, CEO of Austrianova. He emphasized that with this milestone complete, the joint venture is now advancing toward the next steps in producing the clinical product.

A Strategic Alliance for Sustained Delivery

This milestone is the fruit of Klothonova, a joint venture formed in September 2025 between Avaí Bio and Austrianova’s affiliate, SG Austria Pte. Ltd. The partnership is a textbook example of strategic synergy, combining Avaí’s focus on sourcing and developing genetically modified cell lines with Austrianova’s proven delivery technology.

The cells themselves, in-licensed from Klothea Bio, have been engineered to overexpress α-Klotho, a key regulatory protein whose levels in the human body decline with age. Declining Klotho is linked to a host of age-related ailments, from kidney disease to neurodegeneration. The therapeutic hypothesis is simple: restoring Klotho levels could protect against these diseases and promote healthy aging.

However, the challenge has always been delivery. Simply injecting a protein into the bloodstream often results in a short half-life and requires frequent, costly administrations. This is where Austrianova’s proprietary Cell-in-a-Box® technology becomes the partnership’s key differentiator. The technology encapsulates the Klotho-producing cells in a semi-permeable, protective shell. This capsule acts as a miniature bioreactor inside the body, shielding the therapeutic cells from the patient’s immune system while allowing a continuous, sustained release of the α-Klotho protein into the bloodstream.

This approach aims to solve several problems at once: it provides long-term, stable protein levels from a single administration, eliminates the need for patient immunosuppression, and contains the genetically modified cells for enhanced safety. The technology is not entirely new; it has been validated in European clinical trials for other indications, lending a degree of proven performance to the Klothonova venture.

The 'Longevity Protein' and the Long Road to the Clinic

With the cell banks now validated, Klothonova’s focus shifts to the next phase: further characterizing the cells and optimizing the production parameters for the final Cell-in-a-Box® encapsulated product. This involves fine-tuning the process to ensure each dose can be manufactured reliably and at scale, a critical step before seeking regulatory approval to begin human trials.

While this progress is significant, the road ahead remains long and complex. The program is still in the preclinical stage. The next major hurdle will be filing an Investigational New Drug (IND) application with the FDA, which requires a mountain of data on manufacturing, pharmacology, and toxicology. Only after an IND is cleared can Phase 1 human clinical trials—designed primarily to assess safety—begin.

Furthermore, the anti-aging and longevity market is one of the most dynamic and competitive sectors in biotechnology. Competitors are exploring a wide array of strategies, from senolytics that clear out aging cells to other forms of gene and cell therapy. For α-Klotho to become a viable therapy, Klothonova will need to conduct indication-specific trials, demonstrating that sustained delivery of the protein can produce clinically meaningful outcomes in conditions like chronic kidney disease or vascular disease, not just move a biomarker.

Even so, today’s announcement marks a clear point of differentiation. By methodically building their program on a foundation of verified safety and a proven delivery platform, Avaí Bio and Austrianova are signaling a commitment to navigating the complex regulatory landscape with discipline. In a field defined by bold future visions, they have just secured a critical piece of the present.